PEP-Therapy et l’Institut Curie annoncent le traitement des premiers patients dans la phase Ib de l’essai clinique évaluant PEP-010 dans les cancers de l’ovaire et du pancréas 3 weeks ago [#item_full_content] Share this: PEP-Therapy and Institut Curie Announce First Patients Dosed in Phase Ib Clinical Trial Evaluating PEP-010 in Ovarian and Pancreatic CancersDateApril 25, 2024In relation tobiotech newsMBX Biosciences to Participate in the SVB Securities Global Biopharma ConferenceDateJanuary 24, 2023In relation tobiotech newsMBX Biosciences to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDateJanuary 5, 2023In relation tobiotech news